Lupin, together with private equity firms EQT Partners and TPG Capital, is in early-stage discussions to acquire Vitabiotics, the UK’s largest nutraceutical company, owned by the Lalvani family.
The prospective deal could value Vitabiotics at around £1 billion (roughly ₹11,800 crore).
Vitabiotics’ Indian wing, Meyer Vitabiotics, contributes significantly to the company’s global sales representing approximately 20% of its £253 million annual revenue, highlighting the strength of its presence in India.
The acquisition interest from Lupin and the PE firms follows earlier interest from other Indian companies, including Mankind Pharma and Zydus Wellness, both of which reportedly stepped back due to high valuation expectations.
Vitabiotics holds a strong portfolio of nutritional-supplement and wellness brands, including but not limited to Wellwoman, Wellbaby, Pregnacare, Menopace, Feroglobin, Immunace, Visionace, Perfectil and Osteocare — covering segments like paediatrics, women’s health, bone care, immunity and general wellness.
The nutraceutical market in India is currently expanding rapidly, with growing demand for vitamins, minerals and wellness supplements. This broader industry trend helps explain the strategic interest in Vitabiotics from Indian pharma and investment houses
